



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100 Albert Road,  
South Melbourne, Victoria, 3205  
Australia  
Phone: +613 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

### BioDiem Board Change

**Melbourne, 3 May 2022:** Australian vaccine technology company BioDiem Ltd (“BioDiem”) announced that effective today, Mr Hugh Morgan AC, will step down from his non-executive director roles on the boards of BioDiem and its subsidiary, Opal Biosciences Ltd (“Opal”).

Mr Hugh Morgan AC has been chairman of BioDiem since 2005 and is a major shareholder of the company. He is actively involved in many Australian and international advisory roles. Mr Morgan AC said “I feel that this is the right time to step away and I will remain keenly interested in the progress of BioDiem and the LAIV ‘flu technology”.

BioDiem’s chairman, Mr Damien Hannes, said, “Hugh is a well-known and respected Australian and international business figure and his ongoing presence on the board will be greatly missed. Hugh has made a significant contribution in terms of his stewardship as a director and chairman of the board as well as his significant financial investment in BioDiem. Hugh leaves the company in a sound financial position to pursue future commercial opportunities.”

BioDiem’s CEO, Julie Phillips said, “Hugh’s role over many years to forge BioDiem’s commercial success reflects his dedication to the company and its shareholders. As with most biotech companies we have seen ups and downs, but his experience and leadership have led us to this point where our LAIV influenza vaccine technology is marketed in both China and India. Hugh facilitated our licensing agreement to the World Health Organisation in 2011, with Serum Institute of India in 2011 and Changchun BCHO Biotechnology Co, China in 2012. From those efforts we are seeing the financial rewards.”

Mr Hugh Morgan AC is Principal of First Charnock Pty Ltd; Emeritus Director of the Commonwealth Business Council; an Honorary Member of the Business Council of Australia; Chairman of the Order of Australia Association Foundation Limited; Trustee Emeritus of The Asia Society New York; Chairman Emeritus of the Asia Society AustralAsia Centre; Member of the Asia Society Australia Advisory Council; and President of the National Gallery of Victoria Foundation.

- ENDS -

### About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem’s business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem’s lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

Biodiem has two commercial licences:

- Changchun BCHO Biotechnology Co (China) launched Defluvac™ in China in August 2020; and
- Serum Institute of India’s Nasovac-S™ is marketed in India.

## Further information

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9692 7240

Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

Twitter @biodiem @opalbiosciences